---
schema_version: "secwatch.filing_event.v1"
accession: "0000926617-22-000054"
form_type: "8-K"
ticker: "AWHL"
cik: "0000926617"
company_name: "Aspira Women's Health Inc."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-22T00:29:28.933534+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aspira Women's Health Q3 product revenue up 26% to $2.0M; CFO departing Dec 1

## Summary
- Q3 product revenue $2.037M (+26% YoY); Ova1Plus volume 5,524 (+29% YoY); gross margin 57%.
- CFO Robert Beechey to depart Dec 1; will serve as consultant during successor search.
- OvaWatch launch planned Q4 2022; ovarian cancer portfolio rebranded as OvaSuite.
- Sponsored research agreement with Harvard Dana Farber, Brigham & Women's, and Medical Univ. of Lodz for endometriosis test.
- Co-marketing with BioReference launched in Q4; raised $9M gross ($7.7M net) in public offering.

## SEC filing metadata
- accession: 0000926617-22-000054
- form_type: 8-K
- ticker: AWHL
- cik: 0000926617
- company_name: Aspira Women's Health Inc.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/926617/000092661722000054/0000926617-22-000054-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/926617/000092661722000054/awh-20221110x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000926617-22-000054
- JSON: https://secwatch.observer/filing/0000926617-22-000054.json
- Plain text: https://secwatch.observer/filing/0000926617-22-000054.txt

## Key facts
- Earnings Releases
  Aspira Women's Health Inc. reported the third quarter ended September 30, 2022 results: revenue $2,037,000.
  - Period: the third quarter ended September 30, 2022
  - Revenue: $2,037,000
  - Result: reported results
  source text: wish Bob all the best in his future endeavors.”   Highlights of Third Quarter 2022 vs. Third Quarter 2021 · Product revenue for the three months ended September 30, 2022 was $2,037,000 compared to $1,617,000 for the same period in 2021, an increase of 26%. The number of Ova1Plus tests performed during the quarter increased 29% to 5,524 compared to 4,281 for the
  evidence_url: https://www.sec.gov/Archives/edgar/data/926617/000092661722000054/0000926617-22-000054-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.